Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-030 - Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

      Presenter: Federico Cappuzzo

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-048 - Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial

      Presenter: Federico Cappuzzo

      • Abstract

      Loading...

  • +

    P2.14 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics

    • 17:15 - 19:15
    • 8/08/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
    • +

      P2.14-02 - TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial

      Presenter: Lorenza Landi

      • Abstract

      Loading...

  • +

    MA13 - Update on ROS1 Inhibitors and New Pathways

    • 12:00 - 13:00
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      Session Moderator

      12:52 - 13:00  |  Presenter: Lorenza Landi

      • Abstract

      Loading...

    • +

      Session Moderator

      12:52 - 13:00  |  Presenter: Jii Bum (Joy) Lee

      • Abstract

      Loading...

    • +

      MA13.01 - Session Introduction

      12:00 - 12:01  |  Presenter: Lorenza Landi

      • Abstract

      Loading...

    • +

      MA13.02 - Session Introduction

      12:01 - 12:02  |  Presenter: Jii Bum (Joy) Lee

      • Abstract

      Loading...

    • +

      MA13.03 - Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies

      12:02 - 12:07  |  Presenter: Sai-Hong Ignatius Ou

      • Abstract

      Loading...

    • +

      MA13.04 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

      12:07 - 12:12  |  Presenter: Yun Fan

      • Abstract

      Loading...

    • +

      MA13.05 - TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions

      12:12 - 12:17  |  Presenter: Igor Odintsov

      • Abstract

      Loading...

    • +

      MA13.06 - Discussant

      12:17 - 12:27  |  Presenter: Lorenza Landi

      • Abstract

      Loading...

    • +

      MA13.07 - TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC

      12:27 - 12:32  |  Presenter: Benjamin Levy

      • Abstract

      Loading...

    • +

      MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation

      12:32 - 12:37  |  Presenter: Jonathan Riess

      • Abstract

      Loading...

    • +

      MA13.09 - Time from Immune Checkpoint Inhibitor to Sotorasib Use Correlates with Risk of Hepatotoxicity in Non-small Cell Lung Cancer

      12:37 - 12:42  |  Presenter: Sagar Rakshit

      • Abstract

      Loading...

    • +

      MA13.10 - Discussant

      12:42 - 12:52  |  Presenter: Paolo Bironzo

      • Abstract

      Loading...

    • +

      MA13.11 - Live Q&A

      12:52 - 13:00

      • Abstract

      Loading...